Pediatric langerhans cell histiocytosis: single center experience over a 17-year period
dc.contributor.author | Ince, Dilek | |
dc.contributor.author | Demirag, Bengu | |
dc.contributor.author | Ozek, Gulcihan | |
dc.contributor.author | Erbay, Ayse | |
dc.contributor.author | Ortac, Ragip | |
dc.contributor.author | Oymak, Yesim | |
dc.contributor.author | Kamer, Serra | |
dc.contributor.author | Yaman, Yontem | |
dc.contributor.author | Kundak, Selcen | |
dc.contributor.author | Vergin, Canan | |
dc.date.accessioned | 2019-10-27T23:09:09Z | |
dc.date.available | 2019-10-27T23:09:09Z | |
dc.date.issued | 2016 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | This study aimed to analyze children with the diagnosis of Langerhans cell histiocytosis (LCH) who were diagnosed and treated between 1998-2015. Medical records were evaluated retrospectively for clinical and laboratory features, treatment details, and outcome. There were 20 patients, the median age of diagnosis was 37 months, M/F ratio: 1.5. Nine had single system (SS), 11 had multisystem (MS) LCH. Spontaneous regression occurred in three infants with skin limited LCH. Eight patients had risk organ involvement in MS-LCH group. The curettage alone was performed in only one case. Patients received LCH-II/LCH-III based chemotherapy schema. Radiotherapy was performed to vertebral disease and residual craniofacial bone disease in four cases. The regression and relapse rates were 100% and 33% for SS-LCH. The regression and relapse rates were 73%, and 18% for MS-LCH. Two infants with MS-LCH died despite chemotherapy. Pulmonary and liver involvements affected outcome adversely in MS-LCH. Multidisciplinary treatment approaches are needed. | en_US |
dc.identifier.endpage | 355 | en_US |
dc.identifier.issn | 0041-4301 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 28276205 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 349 | en_US |
dc.identifier.uri | https://hdl.handle.net/11454/52540 | |
dc.identifier.volume | 58 | en_US |
dc.identifier.wos | WOS:000398205800001 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Turkish J Pediatrics | en_US |
dc.relation.ispartof | Turkish Journal of Pediatrics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Langerhans cell histiocytosis | en_US |
dc.subject | children | en_US |
dc.subject | treatment | en_US |
dc.title | Pediatric langerhans cell histiocytosis: single center experience over a 17-year period | en_US |
dc.type | Article | en_US |